Bariatric Surgery for Monogenic Non-syndromic and Syndromic Obesity Disorders

Niels Vos 1 · Sabrina M. Oussaada 2 · Mellody I. Cooiman 3 · Lotte Kleinendorst 1 · Kasper W. ter Horst 2 · Eric J. Hazebroek 3 · Johannes A. Romijn 4 · Mireille J. Serlie 2 · Marcel M. A. M. Mannens 5 · Mieke M. van Haelst 1, 6

Published online: 30 July 2020 © The Author(s) 2020

Abstract
Purpose of Review The global prevalence of obesity has increased rapidly over the last decades, posing a severe threat to human health. Currently, bariatric surgery is the most effective therapy for patients with morbid obesity. It is unknown whether this treatment is also suitable for patients with obesity due to a confirmed genetic defect (genetic obesity disorders). Therefore, this review aims to elucidate the role of bariatric surgery in the treatment of genetic obesity.

Recent Findings In monogenic non-syndromic obesity, an underlying genetic defect seems to be the most important factor determining the efficacy of bariatric surgery. In syndromic obesity, bariatric surgery result data are scarce, and even though some promising follow-up results have been reported, caution is required as patients with more severe behavioral and developmental disorders might have poorer outcomes.

Summary There is limited evidence in support of bariatric surgery as a treatment option for genetic obesity disorders; hence, no strong statements can be made regarding the efficacy and safety of these procedures for these patients. However, considering that patients with genetic obesity often present with life-threatening obesity-related comorbidities, we believe that bariatric surgery could be considered a last-resort treatment option in selected patients.

Keywords Obesity · Genetics · MC4R · Bariatric surgery · PWS

Introduction

Obesity is one of the leading health problems globally. According to the World Health Organization (WHO), the global number of patients suffering from obesity has almost tripled over the past 45 years, resulting in an increased prevalence of obesity-associated comorbidities, including cardiovascular diseases and diabetes. These comorbidities are the

Sabrina M. Oussaada and Mellody I. Cooiman contributed equally to this work.

This article is part of the Topical Collection on Genetics

Electronic supplementary material The online version of this article (https://doi.org/10.1007/s11892-020-01327-7) contains supplementary material, which is available to authorized users.
most common causes of death worldwide [1, 2]. To maintain a healthy weight, a balance between energy intake and energy expenditure is required [3]. An energy imbalance, with a relatively larger energy intake than expenditure, can lead to obesity, which is defined as a body mass index (BMI) ≥ 30 kg/m² for adults or ≥ 2 or 3 standard deviations (SD) for children over or under the age of 5 years old, respectively [2]. Obesity is a complex multifactorial disorder caused by the interplay of environmental and genetic factors [4, 5]. An underlying genetic cause can be identified in 5–10% of patients with severe and/or early-onset obesity [5–10]. A defect in one (monogenic) or multiple genes (polygenic) can result in obesity. This can be isolated (non-syndromic obesity) or in a more complex clinical presentation, where apart from obesity, other organ systems are affected, with or without intellectual deficit (syndromic obesity). Apart from monogenic and polygenic causes, there can also be epigenetic changes that play a role in the pathogenesis of obesity, as has been recently described by Rohde et al. [11].

In general, weight loss is achieved by changing the energy balance to a point where energy expenditure exceeds intake. Initial therapeutic options focus on lifestyle interventions aimed at reducing dietary intake, increasing physical activity, treating underlying pathology, and/or pharmacological strategies. However, when conservative therapeutic options fail to result in sustainable weight loss and morbid or severe obesity with associated comorbidities persists (respectively, BMI > 40 kg/m² and BMI > 35 kg/m² in adults), bariatric surgery becomes a viable treatment option.

Bariatric surgery is the most effective treatment for patients with severe or morbid obesity [12]. Nowadays, the most performed surgical techniques include sleeve gastrectomy (SG) and Roux-en-Y gastric bypass (RYGB). Adjustable gastric banding (AGB), a technique widely performed in the past, showed disappointing results in the long term and is as such no longer a standard procedure [13]. Besides reducing stomach volume and altering food passage through the intestines, the neuroendocrine and gut-brain axis alterations are thought to play a significant role in the weight loss response [14–16].

Although most patients experience favorable effects of bariatric surgery, inter-individual variability in surgical outcomes is observed [17]. Several etiological factors, such as differences in the underlying pathophysiology of obesity can cause insufficient weight loss or weight regain. Concerning monogenic non-syndromic and syndromic obesity, it is hypothesized that some patients might not benefit from certain types of bariatric surgery when compared with patients with non-genetic obesity. This review provides an overview of the current knowledge of bariatric surgery outcomes in patients with a proven genetic form of obesity and aims to provide recommendations concerning the most suitable treatments in various genetic obesity disorders.

**Bariatric Surgery for the Treatment of Non-syndromic Genetic Obesity**

Non-syndromic genetic obesity is usually the result of a defect in the leptin-melanocortin pathway (Fig. 1). This pathway plays an essential role in energy homeostasis. Signals from peripheral tissues are processed in the hypothalamus, regulating food intake and thus affecting body weight. Most genes involved in this pathway have been extensively studied and include MC4R, LEPR, POMC, PCSK1, and SIM1 [18–21].

**Melanocortin-4-Receptor**

The most frequent cause of non-syndromic genetic obesity is a mutation in the melanocortin-4-receptor (MC4R) gene. Mutations in this gene typically lead to a defect of the melanocortin-4-receptor, resulting in a phenotype of early-onset severe obesity with hyperphagia [23, 24]. Carriers of a single MC4R mutation are typically less severely affected than patients with compound heterozygous or homozygous mutations [25]. Bariatric surgery outcomes of patients with obesity resulting from MC4R gene defects (heterozygous, compound heterozygous, and homozygous mutations) have been described.

A 3-year follow-up study showed poor results of AGB in nineteen patients with MC4R mutations. There was 18% less total weight loss in carriers of an MC4R mutation, compared with non-carriers (p = 0.003). In addition, there were more gastric complications (mean 0.303 ± 0.060 SEM versus 0.057 ± 0.010 SEM; p < 0.001) and reoperations (57.9% versus 14.2%, p ≤ 0.001) in the MC4R mutation carriers, compared with non-carriers. However, when reoperation with RYGB occurred, weight loss was similar between the two groups. In this specific cohort, a higher frequency of binge eating disorder (BED) was observed in patients with MC4R mutations (100% versus 18.1%; p < 0.001), which is thought to explain, at least in part, the difference in outcome after AGB [26]. In six other studies, no differences in outcomes were seen 1 year after AGB or RYGB [27–29], 1 to 5 years after AGB or SG [30, 31], and 84 months after RYGB [32] between heterozygous MC4R mutation carriers compared with non-carriers. Furthermore, a case report with long-term follow-up results showed beneficial effects of RYGB in one patient with an MC4R mutation (76% excess weight loss after almost 5 years of follow-up) [33].

Homozygous loss-of-function (LOF) mutations in MC4R have been described in four pediatric patients who underwent SG. While initial results were promising in all patients, one patient had weight regain after 5 years of follow-up. Nonetheless, the authors state that SG is a suitable option for pediatric patients with severe obesity and homozygous MC4R mutations [34].
In a large recent Swiss study, MC4R analysis was performed in 872 patients who received bariatric surgery, revealing fourteen MC4R gene variants. Of these variants, eleven were previously described: nine LOF (of which two were found in homozygous form) and two gain-of-function (GOF) variants. Surgical techniques used in this cohort were AGB, RYGB, or a combination of the two (hybrid; HYB). Patients with MC4R variants showed poorer outcomes, with more complications and reoperations after bariatric surgery. This is potentially attributable to the AGB component. However, weight loss was similar (BMI loss 13–14 kg/m² on average in MC4R variant carriers versus 12 kg/m² in non-carriers, percentages not shown). The authors of this study recommend MC4R analysis before surgery in order to choose the right type of surgery [35•]. The reported MC4R gene variants in this study were, however, not all (likely) pathogenic, making it hard to draw firm conclusions.

In our recently reported large bariatric surgery cohort, consisting of 1014 patients, an MC4R mutation was found in 1%. No differences in outcomes between MC4R mutation carriers and non-carriers were observed after RYGB after up to 2 years of follow-up. However, SG was less effective in MC4R mutation carriers compared with the rest of the cohort. Therefore, RYGB might be more suitable for patients with an MC4R mutation than SG [36••].

**Leptin Receptor**

Another important gene in this leptin-melanocortin pathway is the leptin receptor (LEPR) gene. Biallelic genetic defects in this gene are rare, and only 88 patients with a homozygous or compound heterozygous LEPR gene mutation have thus far been described in the literature. Patients with biallelic LEPR mutations typically show hyperphagia and early-onset obesity, among other endocrine disturbances [37]. Of those 88

---

**Fig. 1** The leptin-melanocortin pathway and its effect on energy balance. Reprinted from the *Clinical Molecular Medicine: Principles and Practice* (p.80), by L. Kleinendorst and M. M. van Haelst, published by Elsevier, Copyright © 2020 by Elsevier Inc. Reprinted with permission [22]
patients, six had bariatric surgery. Bariatric surgery was unsuccessful in the three females with a biallelic LEPR mutation; they all regained their lost weight at follow-up. Two female patients underwent RYGB; one lost 50 kg (22.7% of total body weight) but regained it all during pregnancy [38], and the other had a 45 kg weight loss (27.8% of total body weight) after 17 months but regained 34 kg weight 5 years after surgery [39]. The third female patient received SG. She lost 30 kg and regained 19 kg (% of total weight not reported) within an unknown time frame [40••]. The three males with biallelic LEPR mutations that underwent bariatric surgery all showed good results. The first patient had a weight loss of 46 kg (28%) a year after AGB and regained it after slippage of the band. A second gastropasty resulted in a weight loss of 20%, which he maintained after 8 years of follow-up [41]. The second male patient was a 14-year-old boy who lost 47 kg after AGB and regained 10 kg after slippage of the band. His BMI changed from 53.7 preoperatively to 41.6 kg/m² (−22.5%) after a follow-up period of 15 years [40••]. The third male patient had a 44% weight loss, 9 months after gastropasty, but no long-term follow-up data were reported [39]. It is interesting to see a sex-specific difference in outcomes in patients carrying biallelic LEPR mutations. Sex differences are more often described in patients with biallelic LEPR mutations [42]. However, no firm conclusions can be drawn on such a heterogeneous group, with only a small number of patients.

Pro-opiomelanocortin

The pro-opiomelanocortin (POMC) gene is another well-studied gene in the leptin-melanocortin pathway. POMC is cleaved into adrenocorticotropic (ACTH), β-endorphin, and multiple melanocyte-stimulating hormones (MSHs; α-MSH, β-MSH, and multiple γ-MSHs). These hormones are called melanocortins, and they bind to the melanocortin receptors (MCRs). Four different MCRs show different responses upon binding. MC1R stimulation affects skin and hair pigmentation, whereas MC2R activation results in cortisol production, and MC3R and MC4R (as described above) are important in the regulation of food intake and energy homeostasis [43–45]. Patients with biallelic POMC gene mutations present with a POMC deficiency syndrome, characterized by red hair, pale skin, adrenal insufficiency, and early-onset obesity. Heterozygous POMC mutations result in a susceptibility to childhood obesity [43, 46]. Little is known about the effectiveness of bariatric surgery in the treatment of obesity in patients with POMC mutations.

Two studies describe patients with POMC variants that undergo AGB or RYGB [26, 38]. In one of these studies, it is unlikely that the reported variants are pathogenic and bariatric surgery outcome results were not different from the rest of the cohort [26]. In our recent study, twelve patients with heterozygous pathogenic POMC variants responded well to SG and RYGB up to 2 years of follow-up [36••].

Other Monogenic Forms of Obesity

Less is known about the other important components of the leptin-melanocortin pathway. These components include the single-minded homolog 1 (SIM1) and proprotein convertase subtilisin/kexin type 1 (PCSK1) genes.

SIM1 encodes a transcription factor that is essential for the development of part of the hypothalamus (paraventricular, anterior periventricular, and supraoptic nuclei). A defective SIM1 gene is associated with hyperphagia and severe early-onset obesity [47]. In our previous study, one patient with a heterozygous SIM1 mutation is described with a revisional RYGB after initially receiving AGB. After 36 months, a weight loss of more than 20% was maintained. Five other patients were carriers of single variants of unknown significance in SIM1, of which one has recently been reclassified to likely pathogenic after functional assessment [36, 48]. This patient had a 28.8% total body weight loss after 2 years of follow-up after RYGB.

PCSK1 is responsible for the synthesis of prohormone convertase 1/3 (PC1/3). This convertase is important for the cutting of proteins, like POMC (resulting in the production of melanocortins) [49]. Defects in this gene result in a broad phenotype, including obesity, endocrine manifestations (hypogonadotropic hypogonadism, changes in adrenal and thyroid functioning, poor regulation of blood glucose), and malabsorptive diarrhea [50]. Our previous study described five patients with pathogenic PCSK1 mutations, who underwent RYGB, resulting in a total weight loss of over 20% for all three patients at 1- to 3-year follow-up. No differences in outcomes after the different procedures were observed compared with the rest of our cohort [36••]. At present, there are no other published studies that clearly describe the outcomes of bariatric surgery in individuals with a confirmed molecular cause of non-syndromic obesity.

An overview of the studies that were included in this review is provided in Table 1.

Bariatric Surgery for the Treatment of Syndromic Obesity

Syndromic obesity is defined as adiposity combined with dysmorphic features, organ-specific congenital anomalies, and/or developmental delay/intellectual disability. Currently, more than 79 obesity syndromes have been described [51], of which Prader-Willi and Bardet-Biedl syndromes are most frequently reported [3]. In addition to general weight loss measures, such as lifestyle interventions, cognitive behavioral therapy, or pharmacotherapy, there are no specific evidence-based
Table 1  Overview of the included articles (n = 23) on bariatric surgery outcomes in patients with genetic obesity

| Author, year          | Total cohort (n) | Genetic defect/ disorder | Genetic obesity, (n)* | Surgical technique | Follow-up (years) | Results at follow-up                                                                 |
|-----------------------|-----------------|--------------------------|----------------------|-------------------|-------------------|--------------------------------------------------------------------------------------|
| **Non-syndromic**     |                 |                          |                      |                   |                   |                                                                                      |
| Nunziata et al. (2019), review | 57              | Biallelic LEPR mutations | 6                    | AGB, RYGB, SG, gastroplasty | 0.75–15 | Long-lasting weight loss in males (n = 3). Weight regain in females (n = 3)          |
| Huvenne et al. (2015) | 12              | Biallelic LEPR mutations | 2                    | Gastric bypass, gastroplasty | ?–15   | See Nunziata et al. (2019)                                                          |
| Le Beyec et al. (2013) | 1               | Biallelic LEPR mutations | 1                    | Gastric banding, gastroplasty | 8      | See Nunziata et al. (2019)                                                          |
| Nizard et al. (2012)  | 1               | Biallelic LEPR mutations | 1                    | Abdominoplasty, gastric bypass | 2      | See Nunziata et al. (2019)                                                          |
| Mul et al. (2012)     | 46              | MC4R                     | 5                    | SG                | 1      | No difference in outcome                                                            |
| Bonmefond et al. (2016) | 872           | MC4R                     | 64**                 | AGB, RYGB, Hybrid | 6      | Significantly worse outcomes and higher rate of BED and LOC in MC4R variant** carriers, compared with non-carriers. Variants were GOF (n = 47) and LOF (n = 17) |
| Jelin et al. (2016)   | 4               | MC4R deficiency          | 4                    | SG                | 0.4–5  | Significant short-term weight loss in all patients. Long-term weight regain in one patient. Children |
| Elkhenini et al. (2014) | 1              | MC4R                     | 1                    | RYGB              | 5      | 76% EWL                                                                              |
| Moore et al. (2014)   | 1433            | MC4R                     | 18**                 | RYGB              | 7      | Similar weight loss for MC4R variant** carriers compared with controls                |
| Censani et al. (2014) | 135             | MC4R                     | 4                    | AGB, SG           | 1–5    | 36–85% EWL after AGB in three patients. 96% EWL after SG in one patient             |
| Hatoun et al. (2012)  | 972             | MC4R                     | 15                   | RYGB              | 3      | Similar weight loss in patients with MC4R mutations, compared with non-carriers     |
| Valette et al. (2012) | 648             | MC4R                     | 9                    | AGB, RYGB         | 1      | No difference in weight loss                                                        |
| Aslan et al. (2011)   | 92              | MC4R                     | 4                    | AGB, RYGB         | 1      | 66% EWL compared with 70% EWL in controls                                           |
| Cooiman et al. (2020) | 1014            | MC4R, PCSK1, POMC, SIM1  | 30                   | RYGB, SG          | 2      | MC4R (n = 11): RYGB more effective than SG                                          |
| Potoczna et al. (2004) | 300             | MC4R, POMC, LEPR         | ??*                  | AGB, RYGB (reoperation) | 3      | MC4R variant** carriers (n = 19) versus controls: 18% less TWL (p = 0.003), higher reoperation rate (57.9% versus 14.2%), and more BED (100% versus 18.1%). POMC variant** carriers (n = 144) and LEPR variant** carriers (n = 247) versus controls: no difference in outcomes |
| **Syndromic**         |                 |                          |                      |                   |                   |                                                                                      |
| Ferrario et al. (2014) | 1               | AHO (PPHP)               | 1                    | SG                | 3      | 46.8% TWL                                                                            |
| Ates et al. (2018)    | 8               | BBS                      | 1                    | SG                | 1      | 28% TWL, Child                                                                      |
| Boscolo et al. (2017) | 1               | BBS                      | 1                    | SG                | 3      | 32.6% TWL                                                                            |
| Martinelli et al. (2019) | 1              | PWS                      | 1                    | SG                | 0.5    | 29.2% EWL, Child                                                                    |
| Cazzo et al. (2018)   | 1               | PWS                      | 1                    | BPD               | 1      | 55% EWL                                                                              |
| Alqahtani et al. (2016) | 96             | PWS                      | 24                   | SG                | 3      | Similar BMI loss after SG compared with controls. Children                            |
therapies for syndromic obesity. Here, we provide an overview of the available evidence on the various bariatric procedures for the treatment of three (monogenic) obesity syndromes (see Table 1). We note that data are limited, since the use of such invasive treatments in patients with genetic obesity syndromes remains controversial, and that there is no international consensus as yet.

Prader-Willi Syndrome

In most cases, Prader-Willi syndrome (PWS) is caused by loss or disruption of the paternal copy of chromosome 15q11.2-13 and has an estimated prevalence of 1:8000–1:50,000 individuals [52, 53]. PWS is characterized by hypotonia, feeding difficulties, and mild dysmorphic features in the neonatal period. As patients become older, a global developmental delay, neuropsychiatric and endocrine manifestations (short stature, hypogonadism, hypothyroidism, adrenal insufficiency), and more distinctive dysmorphic features can be observed. Feeding difficulties typically dissolve after the age of 9 months, and weight increases more rapidly after the age of 2. From around the age of 4 onwards, food intake increases, and excessive eating (hyperphagia) can be observed [54, 55]. This usually results in childhood-onset morbid obesity and its associated complications (obstructive sleep apnea, diabetes mellitus type 2, and hypertension). In fact, the associated complications of their insatiable appetite and uncontrolled weight gain are the leading causes of death during adolescence or early adulthood [56, 57].

Current obesity treatments that focus on changes in feeding behavior/diet, exercise, or hormonal replacement therapy are ineffective for long-term weight loss maintenance in the majority of patients with PWS [58]. Although bariatric procedures, including RYGB, result in long-lasting weight reduction and remission of comorbidities in the majority of patients with obesity in the general population [59], it remains controversial whether or not to perform this invasive therapy in patients with PWS. The pathophysiology of obesity in PWS is different from other forms of genetic obesity; the compulsive food seeking and behavioral problems in PWS are thought to interfere with lifestyle changes needed after bariatric surgery. Previously reported bariatric procedures, including intragastric balloon placement or gastric banding, did not produce favorable weight loss outcomes in patients with PWS [60].

Today’s first-choice weight loss procedures (SG and RYGB) have been studied in one cohort of patients with PWS. SG was performed in 24 pediatric patients with molecularly confirmed PWS, and outcomes were compared with the outcomes of 72 children with obesity without PWS, who were matched for age, gender, and BMI at baseline [61]. Children in the study were 4.9–18.2 years old. After surgery, children with PWS lost considerable body weight, and there were no
apparent differences in postoperative BMI loss between the PWS and control groups up to 3 years after sleeve gastrectomy. However, in the 4th and 5th year of follow-up, the PWS group regained weight, which resulted in a mean (±SD) BMI of 35.9 ± 12.5 kg/m², compared with 25.1 ± 7.0 kg/m² in the control group. This finding suggests that patients with PWS may be more prone to long-term weight regain, but more (complete) data are needed to confirm this trend. No short- or long-term complications were reported.

In addition to this case-control study, there are four single PWS cases reported for which outcomes of sleeve gastrectomy or biliopancreatic diversion were reported. A 25-year-old man with PWS, with a preoperative BMI of 55 kg/m² and impaired glucose tolerance (IGT), underwent an uncomplicated biliopancreatic diversion [62••]. One year after surgery, his BMI had decreased to 38.5 kg/m² (−30%), and his IGT had resolved. A 16-year-old adolescent with PWS and a preoperative BMI of 80.9 kg/m² also suffered from severe obstructive sleep apnea with nocturnal respiratory failure, hypertension, and IGT [63••] and had a reduction in BMI to 64.6 kg/m² (−20.1%) 6 months after SG. Finally, two PWS patients were reported who underwent a biliopancreatic diversion [64•]. The first case was a 25-year-old woman with a decrease in BMI from 55.5 to 41.3 kg/m² after 6 months, corresponding to an excess weight loss (EWL) of 43%. The second case, an 18-year-old woman, with a preoperative BMI of 64.4 kg/m², showed a decrease to 53.9 kg/m² (−16.3%) within 18 months after surgery. Notably, prior treatment with an intragastric balloon had failed to achieve weight loss.

Based on the available observational data, it seems that short-term bariatric surgery-induced weight loss outcomes in patients with PWS are comparable with those achieved in other patients with (non-genetic) obesity. However, these limited data do not (yet) justify the widespread application of bariatric surgery in patients with PWS, as gastric rupture and necrosis have been previously described in patients that did not even undergo bariatric surgery [65]. Long-term outcome needs to be further studied for these patients. Intensive postoperative behavioral therapy and supervision might prevent or delay weight regain, so that bariatric surgery for patients with PWS might reduce obesity-associated morbidity and mortality.

**Bardet-Biedl Syndrome**

Bardet-Biedl syndrome (BBS) is a rare autosomal recessive ciliopathy. BBS is characterized by severe early-onset obesity, intellectual deficit, polydactyly, renal abnormalities, and retinitis pigmentosa [66]. Although more than 20 genes are currently known to be associated with BBS, mutations in BBS1 and BBS10 are identified in the majority of cases [66, 67]. Weight loss strategies focusing on lifestyle changes and pharmacotherapy do not seem to result in sustained weight loss in affected patients [68, 69]. Therefore, other therapies, including bariatric surgery, are being explored. During the last 5 years, two case reports of SG in patients with BBS have been published.

A 37-year-old woman with BBS who had morbid obesity underwent uncomplicated SG [70••]. Her BMI decreased from 40.8 to 27.5 kg/m² (−32.6%) within 36 months after surgery, with additional improvements in glycemic control, hypertension, and non-alcoholic fatty liver disease. Another study examined the effects of SG in adolescents, including one person who was diagnosed with BBS [71••]. The postoperative period of the 14-year-old boy was uneventful. The intervention was associated with a total weight reduction of 28% after 12 months. His blood pressure normalized, and hypertension treatment could be discontinued.

Thus, although the available evidence on modern bariatric surgery techniques in patients with BBS is scarce, the described cases suggest that SG may be a safe and effective treatment for BBS-related obesity, although more studies are needed to support the effectiveness in the long term.

**Albright Hereditary Osteodystrophy**

Albright hereditary osteodystrophy (AHO) is an obesity syndrome with a broad spectrum of manifestations, including short stature, brachydactyly, and subcutaneous calcifications due to resistance to parathyroid hormone (pseudohypoparathyroidism; PHP) [72]. AHO is caused by heterozygous inactivation of the GNAS gene, encoding the alpha chain of the stimulatory G protein [73]. Genomic imprinting induces a variable phenotypic expression [74]. Maternal GNAS inactivation results in the AHO phenotype plus resistance to other hormones, most notably thyroid-stimulating hormone [74]. A loss of expression of GNAS of the paternal allele results in the AHO phenotype without hormonal resistance (pseudopseudohypoparathyroidism; PHP). To our knowledge, no data are available regarding the effects of conservative weight-loss strategies in patients with AHO. However, there is one reported case of bariatric surgery in a patient with AHO.

A 26-year-old woman with PPHP (heterozygous mutation of the paternal GNAS gene), obesity, and type 2 diabetes underwent uncomplicated RYGB [75]. Within the first year after surgery, her BMI decreased from 49.5 to 25.9 kg/m² (−47.7%). Her body weight remained stable during the following 24 months. The effects of this weight loss on glycemic control were not discussed.

**Discussion**

In summary (see Table 1), there is limited high-quality evidence in support of bariatric surgery as a treatment option for genetic obesity. In monogenic non-syndromic obesity, the identification of an MC4R mutation seems to be no contraindication for bariatric surgery. RYGB might be more suitable than SG for patients
with an MC4R mutation. In patients carrying biallelic LEPR mutations, there seems to be a sex-specific effect, where males show better bariatric surgery outcomes. This is however based on only six patients in total. For the other monogenic non-syndromic obesity disorders, bariatric surgery outcome results seem to be similar to those of patients without an identified genetic cause of their obesity, but sample sizes were even smaller. The underlying mechanisms of genetic obesity syndromes are mostly unknown and might involve genetically determined dysregulations of neuronal circuits involved in the control of feeding behavior. Bariatric surgery is not only a restrictive and malabsorptive procedure but also affects the neuroendocrine milieu and the gut-brain axis [14–16]. The positive effect of the procedure on food intake could provide further insight into the neuronal regulation of feeding behavior in patients with these syndromes.

Limitations of the described studies are that some include genetic variants for which the pathogenicity is not certain or for which it is not sure that heterozygosity is the explanation of these patients’ obesity. A higher preoperative BMI is commonly observed in patients with a genetic obesity disorder, making it essential to compare the percentage of total weight or BMI loss, instead of the absolute weight loss in kg, which is frequently done. The rapid development of technology can facilitate further genetic analyses. Cases now being reported as non-genetic could well harbor a (yet unknown) genetic defect that will be identified in the near future. We noticed that some of the studies included in this review describe the application of bariatric surgery in young children. Although the safety of bariatric surgery in children and adolescents has been established in various studies, ethical issues are still a subject of ongoing debate [76, 77].

It would be interesting to systematically assess the effects of bariatric surgery on genetic versus non-genetic obesity. A systematic analysis could function as a tool to predict the effectiveness of surgical interventions in specific genetic obesity disorders. Also, the current rapid growth in knowledge of molecular pathways underlying genetic obesity will provide us with novel insights into the pathophysiological mechanisms in the development of obesity. Finally, we believe that there is an essential role for polygenic and epigenetic factors in the pathophysiology of obesity. Future studies regarding these mechanisms can potentially further explain the difference in outcomes and guide us in the right direction for personalized treatments of specific obesity disorders.

Conclusion

Altogether, no strong statements can be made regarding the efficacy and safety of bariatric surgery procedures in patients with genetic obesity disorders. Our opinion is that available evidence does not (yet) support the widespread application of invasive bariatric procedures for patients with genetic obesity. In addition, since patients with genetic obesity often present with life-threatening obesity-related comorbidities, we believe that bariatric surgery could be considered as a last-resort option in a selection of patients with genetic obesity disorders, after careful consideration by an experienced and multidisciplinary obesity team, including behavioral therapists familiar with hyperphagia and compulsive eating disorders.

Compliance with Ethical Standards

Conflict of Interest The authors declare that they have conflicts of interest.

Human and Animal Rights and Informed Consent For this article, no new studies with human or animal subjects were performed by any of the authors.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

Papers of particular interest, published recently, have been highlighted as:
• Of importance
• Of major importance

1. (WHO) WHO. The top 10 causes of death. 2018.
2. (WHO) WHO. Obesity and overweight. 2020.
3. Oussaada SM, van Galen KA, Cooiman MI, Kleinendorst L, Hazebroek EJ, van Haestl MM, et al. The pathogenesis of obesity. Metabolism. 2019;92:26–36.
4. Bray GA, Kim KK, Wilding JPH. Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation. Obes Rev. 2017;18(7):715–23.
5. Kleinendorst L, Massink MPG, Cooiman MI, Savas M, van der Baan-Slootweg OH, Roelants RJ, et al. Genetic obesity: next-generation sequencing results of 1230 patients with obesity. J Med Genet. 2018;55(9):578–86.
6. Bell CG, Walley AJ, Froguel P. The genetics of human obesity. Nat Rev Genet. 2005;6(3):221–34.
7. Nordang GBN, Busk OL, Tveten K, Hanevik HJ, Fell AKM, Hjelmesaeth J, et al. Next-generation sequencing of the monogenic obesity genes LEP, LEPR, MC4R, PCSK1 and POMC in a Norwegian cohort of patients with morbid obesity and normal weight controls. Mol Genet Metab. 2017;121(1):51–6.
8. Saeed S, Bonnefond A, Manzoor J, Shabbir F, Ayeshia H, Philippe J, et al. Genetic variants in LEP, LEPR, and MC4R explain 30% of
severe obesity in children from a consanguineous population. Obesity (Silver Spring, Md). 2015;23(8):1687–95.

9. Akinci A, Turkkahraman D, Tekedereli I, Ozer L, Evren B, Sahin I, et al. Novel mutations in obesity-related genes in Turkish children with non-syndromic early onset severe obesity: a multicentre study. J Clin Res Pediatr Endocrinol. 2019;11(4):341–9.

10. Hill JO, Wyatt HR, Peters JC. Energy balance and obesity. Circulation. 2012;126(1):126–32.

11. Rohde K, Keller M, la Cour PL, Bluther M, Kovacs P, Botcher Y. Genetics and epigenetics in obesity. Metabolism. 2019;92:37–50.

12. Poirier P, Cornier MA, Mazzone T, Stiles S, Cummings S, Klein S, et al. Bariatric surgery and cardiovascular risk factors: a scientific statement from the American Heart Association. Circulation. 2011;123(15):1683–701.

13. Aarts EO, Dogan K, Koehestanie P, Aufenacker TJ, Janssen IM, Berends FJ. Long-term results after laparoscopic adjustable gastric banding: a mean fourteen year follow-up study. Surg Obes Relat Dis. 2014;10(4):633–40.

14. Peterli R, Steinert RE, Woelnerhanssen B, Peters T, Christoffel-Courtin C, Gass M, et al. Metabolic and hormonal changes after laparoscopic Roux-en-Y gastric bypass and sleeve gastrectomy: a randomized, prospective trial. Obes Surg. 2012;22(5):740–8.

15. Ramon JM, Salvans S, Crous X, Puig S, Goday A, Benaiges D, et al. Effect of Roux-en-Y gastric bypass vs sleeve gastrectomy on glucose and gut hormones: a prospective randomised trial. J Gastrointest Surg. 2012;16(6):1116–22.

16. Youssef A, Emmanuel J, Karra E, Millet Q, Elkalawa M, Jenkinson AD, et al. Differential effects of laparoscopic sleeve gastrectomy and laparoscopic gastric bypass on appetite, circulating acyl-grelin, peptide YY3-36 and active GLP-1 levels in non-diabetic humans. Obes Surg. 2014;24(2):241–52.

17. Inge TH, Coley RY, Bazzano LA, Xanthakos SA, McIntigue K, Arterburn D, et al. Comparative effectiveness of bariatric procedures among adolescents: the PCORnet bariatric study. Surg Obes Relat Dis. 2018;14(9):1374–86.

18. Crowley VE. Overview of human obesity and central mechanisms regulating energy homeostasis. Ann Clin Biochem. 2008;45(Pt 3):245–55.

19. Farooqi IS, O’Rahilly S. Mutations in ligands and receptors of the leptin-melanocortin pathway that lead to obesity. Nat Clin Pract Endocrinol Metab. 2008;4(10):569–77.

20. Farooqi S, O’Rahilly S. Genetics of obesity in humans. Endocr Rev. 2006;27(7):710–8.

21. Mutch DM, Clement K. Unraveling the genetics of human obesity. PLoS Genet. 2006;2(12):e188.

22. Kleindorfer L. Chapter 5 - Molecular basis of obesity disorders. In: Poirier P, Cornier MA, Mazzone T, Stiles S, Cummings S, Klein S, et al. Bariatric surgery and cardiovascular risk factors: a scientific statement from the American Heart Association. Circulation. 2011;123(15):1683–701.

23. Valette M, Poitou C, Le Beyec J, Bouillot JL, Clement K, Czernichow S. Melanocortin-4 receptor mutations and polymorphisms do not affect weight loss after bariatric surgery. PLoS One. 2012;7(11):e48221.

24. Aslan IR, Campos GM, Calton MA, Evans DS, Merriman RB, Vaisse C. Weight loss after Roux-en-Y gastric bypass in obese patients heterozygous for MC4R mutations. Obes Surg. 2011;21(7):930–4.

25. Hatoum IJ, Stylopolous N, Vanhoose AM, Boyd KL, Yin DP, Ellacott KL, et al. Melanocortin-4 receptor signaling is required for weight loss after gastric bypass surgery. J Clin Endocrinol Metab. 2012;97(6):E1023–31.

26. Censani M, Conroy R, Deng L, Oberfield SE, McMahan DJ, Zitsman JL, et al. Weight loss after bariatric surgery in morbidity obese adolescents with MC4R mutations. Obesity (Silver Spring, Md). 2014;22(1):225–31.

27. Mul JD, Begg DP, Alsters SI, van Haften G, Duran KJ, D’ Alessio DA, et al. Effect of vertical sleeve gastrectomy in melanocortin receptor 4-deficient rats. Am J Physiol Endocrinol Metab. 2012;303(1):E103–10.

28. Moore BS, Minshahi YL, Yost EA, Stepanchick AN, Bedrin MD, Styer AM, et al. Long-term weight-loss in gastric bypass patients carrying melanocortin 4 receptor variants. PLoS One. 2014;9(4):e93629.

29. Elkhenni HF, New JP, Syed AA. Five-year outcome of bariatric surgery in a patient with melanocortin-4 receptor mutation. Clin Obes. 2014;4(2):121–4.

30. Jenlin EB, Daggag H, Speer AL, Hameed N, Lessan N, Barakat M, et al. Melanocortin-4 receptor signaling is not required for short-term weight loss after sleeve gastrectomy in pediatric patients. Int J Obes. 2016;40(3):550–3. Paediatric patients with homozygous. MC4R mutations show initial short-term weight loss. At long term, there was weight regain in one patient.

31. Bonnefond A, Keller R, Meyre D, Stuttmann F, Thuillier D, Stefanov DG, et al. Eating behavior, low-frequency functional mutations in the melanocortin-4 receptor (MC4R) gene, and outcomes of bariatric operations: a 6-year prospective study. Diabetes Care. 2016;39(8):1384–92. Carriers of. MC4R variants had poorer outcomes after bariatric surgery. The described variants are not all pathogenic. It is therefore hard to draw firm conclusions.

32. Cooimain MI, Kleindorfer L, Aarts EO, Janssen IMC, van Amstel HKP, Blakemore AI, et al. Genetic obesity and bariatric surgery outcome in 1014 patients with morbid obesity. Obes Surg. 2020;30(2):470–7. Various genetic defects are described. RYGB is more effective than SG in patients with an. MC4R mutation. No significant differences in bariatric surgery outcomes between patients with. PCSK1, POMC, and. SIMI. mutations and non-carriers.

33. Kleindorfer L, Abawi O, van der Kamp HJ, Alders M, Meijers-Heijboer HEJ, van Rossum EFC, et al. Leptin receptor deficiency: a systematic literature review and prevalence estimation based on population genetics. Eur J Endocrinol. 2020;182(1):47–56.

34. Nizard J, Hommergues M, Clément K. Pregnancy in a woman with a leptin-receptor mutation. N Engl J Med. 2012;366(11):1064–5.

35. Hovenne H, Le Beyec J, Pepin D, Allili R, Kherchiche PP, Jeannic Jelin EB, Daggag H, Speer AL, Hameed N, Lessan N, Barakat M, et al. Melanocortin-4 receptor signaling is not required for short-term weight loss after sleeve gastrectomy in pediatric patients. Int J Obes. 2016;40(3):550–3. Paediatric patients with homozygous. MC4R mutations show initial short-term weight loss. At long term, there was weight regain in one patient.

36. Courtois C, Cugnet-Anceau C, Pepin D, Allili R, Cotillard A, Lacorte JM, et al. Homozygous leptin receptor mutation due to uniparental disomy of chromosome 1: response to bariatric surgery. J Clin Endocrinol Metab. 2013;98(2):E397–402.
42. Dehghani M, Mehrjardi M, Dilaver N, Tajamolian M, Enayati S, Ebrahimip S, et al. Potential role of gender specific effect of leptin receptor deficiency in an extended consanguineous family with severe early-onset obesity. Eur J Med Genet. 2018;61:465–7.

43. Krude H, Biehermann H, Luck W, Horn R, Brabant G, Gruters A. Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans. Nat Genet. 1998;19(2):155–7.

44. Millington GW. Proopiomelanocortin (POMC): the cutaneous roles of its melancortin products and receptors. Clin Exp Dermatol. 2006;31(3):407–12.

45. Mountjoy KG, Caron A, Hubbard K, Shome A, Grey AC, Sun B, et al. Desacetyl-alpha-melanocyte stimulating hormone and alpha-melanocyte stimulating hormone are required to regulate energy balance. Mol Metab. 2018;9:207–16.

46. Dubern B, Lubrano-Berthelier C, Mencarelli M, Ersoy B, Frelut ML, Bourgue D, et al. Nutritional and metabolic analysis of the C1R2L variants in French obese children led to the identification of a novel deleterious heterozygous mutation located in the alpha-melanocyte stimulating hormone domain. Pediatr Res. 2008;63(2):211–6.

47. Kubiak AM, Holder JL Jr, Gemelli T, Zinn AR. Sim1 haploinsufficiency impairs melanocortin-mediated anorexia and activation of paraventricular nucleus neurons. Mol Endocrinol. 2006;20(10):2483–92.

48. Blackburn PR, Sullivan AE, Gerassimou AG, Kleinendorst L, Coban C, Frelut ML, et al. Nutritional and metabolic analysis of the Proopiomelanocortin gene in French obese children led to the identification of a novel deleterious heterozygous mutation located in the alpha-melanocyte stimulating hormone domain. Pediatr Res. 2008;63(2):211–6.

49. Chen C, Visootsak J, Dills S, Graham JM Jr. Prader-Willi syndrome: current understanding of cause and diagnosis. Am J Med Genet. 1990;35(3):319–32.

50. Stijnen P, Ramos-Molina B, Martin MG, Lindberg I. PCSK1 variants and human obesity. Prog Mol Biol Transl Sci. 2016;140:47–76.

51. Stijnen P, Ramos-Molina B, O’Rahilly S, Cremers JW. PCSK1 mutations and human endocrinopathies: from obesity to gastrointestinal disorders. Endocr Rev. 2016;37(4):347–71.

52. Kaur Y, de Souza RJ, Gibson WT, Meyre D. A systematic review of genetic syndromes with obesity. Obes Rev. 2017;18(6):603–34.

53. Butler MG, Prader-Willi syndrome: current understanding of cause and diagnosis. Am J Med Genet. 1990;35(3):319–32.

54. Cossu P, Visootsak J, Dills S, Graham JM Jr. Prader-Willi syndrome: an update and review for the primary pediatrician. Clin Pediatr (Philadelphia). 2007;46(7):580–91.

55. Miller JL, Lynn CH, Driscoll DC, Goldstone AP, Gold JA, Kimonis V, et al. Nutritional phases in Prader-Willi syndrome. Am J Med Genet A. 2011;155A(5):1040–9.

56. Driscoll DJ, Miller JL, Schwartz S, Cassidy SB. Prader-Willi syndrome. In: Adlam MP, Ardingh H, Pagon RA, Wallace SE, Bean LJH, Stephens K, et al., editors. GeneReviews®. Seattle (WA): University of Washington, Seattle; 1998. p. 1–6.

57. Driscoll DJ, Miller JL, Schwartz S, Cassidy SB. Prader-Willi syndrome. In: Adlam MP, Ardingh H, Pagon RA, Wallace SE, Bean LJH, Stephens K, et al., editors. GeneReviews®. Seattle (WA): University of Washington, Seattle; 1998. p. 1–6.

58. Lima VP, Emerich DR, Mesquita LM, Patemez AC, Carreiro LR, Pina Neto JM, et al. Nutritional intervention with hypocaloric diet for weight control in children and adolescents with Prader-Willi syndrome. End Behav. 2016;23:189–92.

59. le Roux CW, Heneghan HM. Bariatric surgery for obesity. Med Clin N Am. 2018;102(1):165–82.

60. Scheimann AO, Butler MG, Gourash L, Cuffari C, Klish W. Critical analysis of bariatric procedures in Prader-Willi syndrome. J Pediatr Gastroenterol Nutr. 2008;46(1):80–3.

61. Alqahtani AR, Elahmedi MO, Al Qahtani AR, Lee J, Butler MG. Laparoscopic sleeve gastrectomy in children and adolescents with Prader-Willi syndrome: a matched-control study. Surg Obes Relat Dis. 2016;12(1):100–10. This study describes the effect of SG in children with PWS and shows similar BMI loss up to 3 years after surgery, compared with controls.

62. Zucco E, Gestea MC, Utini MP, Chaim FDM, Candido EC, Jarlovsky L, et al. Bariatric surgery in individuals with severe cognitive impairment: report of two cases. Sao Paulo Med J. 2018;136(1):84–8. One child with PWS responded well to BPD (55% excess weight loss after 1 year).

63. Martinelli V, Chiappelli M, Pellegrino E, Zugnoni M, Caccialanza R, Muggia C, et al. Laparoscopic sleeve gastrectomy in an adolescent with Prader-Willi syndrome: psychosocial implications. Nutrition. 2019;61:67–9. One child with PWS responded well to SG (29.2% excess weight loss after 6 months).

64. Michalik M, Frask A, Lech P, Zdrojewski M, Doboszynska A. The usefulness of biliopancreatic diversion/Scopinaro operation in treatment of patients with Prader-Willi syndrome. Wideochir Inne Tech Maloinwazjyne. 2015;10(2):324–7. Two patients with PWS responded well to BPD (25 to 43% excess weight loss after 18 and 6 months respectively).

65. Stevenson DA, Heinemann J, Angulo M, Butler MG, Loker J, Rupe N, et al. Gastric rupture and necrosis in Prader-Willi syndrome. J Pediatr Gastroenterol Nutr. 2007;45(2):272–4.

66. Forsythe E, Beales PL. Bardet-Biedl Syndrome. In: Adam MP, Ardingh H, Pagon RA, Wallace SE, Bean LJH, Stephens K, et al., editors. GeneReviews®. Seattle (WA): University of Washington, Seattle; 2020,105(1).

67. Forsythe E, Kenny J, Baccelli C, Beales PL. Managing Bardet-Biedl syndrome now and in the future. Front Pediatr. 2018;6:23.

68. Daskalakis M, Till H, Kiss W, Weiner RA. Roux-en-Y gastric bypass in an adolescent patient with Bardet-Biedl syndrome, a monogenic obesity disorder. Obes Surg. 2010;20(1):121–5.

69. Uday S, Ali M, Azam W, Barrett T. Effect of dietetic management on weight in children with Bardet-Biedl syndrome. Endocrine Abstracts 2015.

70. Boscolo M, Fery F, Cnop M. Beneficial outcomes of sleeve gastrectomy in a morbidly obese patient with Bardet-Biedl Syndrome. J Endocr Soc. 2017;14(3):37–22. One patient with BBS, good response to SG (32.6% total weight loss after 3 years).

71. Artes U, Ergun E, Gollu G, Sozdyar S, Can OS, Yagmurla M. Pediatric laparoscopic sleeve gastrectomy in Turkey: short-term results. Pediatr Int. 2018;60(5):461–6. One patient with BBS, good response to SG (28% total weight loss after 1 year).

72. Albright F, Forbes AP, Henneman PH. Pseudo-pseudohyoparathyroidism. Trans Assoc Am Phys. 1983;65:337–50.

73. Patten JL, Johns DR, Valle D, Elil C, Gruppussa PA, Steeko G, et al. Mutation in the gene encoding the stimulatory G protein of adenylyl cyclase in Albright’s hereditary osteodystrophy. N Engl J Med. 1990;322(20):1412–9.

74. Weinstein LS, Yu S, Warner DR, Liu J. Endocrine manifestations of stimulatory G protein alpha-subunit mutations and the role of genomic imprinting. Endocr Rev. 2001;22(5):675–705.

75. Ferrario C, Gastaldi G, Portmann L, Giusti V. Bariatric surgery in adolescents? Eur J Endocrinol. 2017;176(4):D1–D15.

76. Kumar S, Kelly AS. Review of childhood obesity: from epidemiological, etiology, and comorbidities to clinical assessment and treatment. Mayo Clin Proc. 2017;92(2):251–65.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.